Quetiapine and norquetiapine in plasma and cerebrospinal fluid of schizophrenic patients treated with quetiapine: Correlations to clinical outcome and HVA, 5-HIAA, and MHPG in CSF

Journal of Clinical Psychopharmacology

Volumn 30, Issue 5, 2010, Pages 496-503

  Nikisch, Georg ^a   Baumann, Pierre ^b   Wiedemann, Georg ^a   Kiessling, Bernhard ^a   Weisser, Heike ^a   Hertel, Andreas ^a   Yoshitake, Takashi ^c   Kehr, Jan ^c   Mathé, Aleksander A ^c  

^a KLINIKUM FULDA   (Germany)

^b Hopital de Cery   (Switzerland)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

CSF; monoamine metabolites; norquetiapine; plasma; quetiapine; schizophrenia

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; 5 HYDROXYINDOLEACETIC ACID; DRUG METABOLITE; HOMOVANILLIC ACID; NORQUETIAPINE; QUETIAPINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; DIBENZOTHIAZEPINES; FEMALE; HOMOVANILLIC ACID; HUMANS; HYDROXYINDOLEACETIC ACID; MALE; METHOXYHYDROXYPHENYLGLYCOL; MIDDLE AGED; SCHIZOPHRENIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77957277692     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181f2288e     Document Type: Article

References (66)

1. Freedman R. Schizophrenia. N Engl J Med. 2003;349: 1738-1749. (Pubitemid 37315012)
2. Koreen AR, Siris SG, Chakos M, et al. Depression in first-episode schizophrenia. Am J Psychiatry. 1993;150: 1643-1648. (Pubitemid 23325945)
3. Keck JPE, Strakowski SM, McElroj SL, et al. The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia. J Clin Psychiatry. 2000;61: 4-9.
4. American Psychiatric Association. Practice guidelines for treatment of patients with schizophrenia, 2nd ed. Am J Psychiatry. 2004;161: 1-56.
5. Keefe RS, Sweeney JA, Gu H, et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry. 2007;164: 1061-1071. (Pubitemid 47121395)
6. Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry. 2007;164: 415-427.
7. McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006;163: 600-610.
8. Bagnall AM, Jones L, Grnnelly L, et al. A systematic review of antipsychotic drugs in schizophrenia. Health Technol Assess. 2003;7: 1-193. (Pubitemid 36903285)
9. Lindström E, Eberhard J, Levander S. Five-year follow-up during antipsychotic treatment: efficacy, safety, functional and social outcome. Acta Psychiatr Scand Suppl. 2007;435: 5-16. (Pubitemid 47621730)
10. Rosenheck RA, Davis S, Covell N, et al. Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial. Schizophr Res. 2009;107: 22-29.
11. Small JG, Hirsch SR, Arvanitis LA, et al. Quetiapine in patients with schizophrenia. A high-and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry. 1997;54: 549-557. (Pubitemid 27258553)
12. Arvanitis LA, Miller BG. Multiple fixed doses of FSeroquel- (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry. 1997;42: 233-246.
13. Peuskens J, Link CG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand. 1997;96: 265-273. (Pubitemid 27428238)
14. Kasper S, Müller-Spahn F. Review of quetiapine and its clinical applications in schizophrenia. Expert Opin Pharmacother. 2000;4: 783-801.
15. Derry S, Moore RA. Atypical antipsychotics in bipolar disorder: systematic review of randomised trials. BMC Psychiatry. 2007;16: 40. (Pubitemid 47593124)
16. Calabrese JR, Keck PE Jr, Mac Fadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005;162: 1353-1360.
17. Keck PE Jr. Bipolar depression: a new role for atypical antipsychotics? Bipolar Disord. 2005;7: 34-40. (Pubitemid 41065247)
18. Yatham LN, Liddle PF, Shiah IS, et al. PET study of [(18)F]6-fluoro-L- dopa uptake in neuroleptic-and mood-stabilizer-naive first-episode nonpsychotic mania: effects of treatment with divalproex sodium. Am J Psychiatry. 2002;48: 768-774.
19. Farah A. Atypicality of atypical antipsychotics. Prim Care Companion J Clin Psychiatry. 2005;7: 268-274. (Pubitemid 44371604)
20. Farde L, Nordström AL, Wiesel FA, et al. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry. 1992;495: 38-44.
21. Kapur S, Zipursky R, Jones C, et al. A positron emission tomography study of quetiapine in schizophrenia. Arch Gen Psychiatry. 2000;57: 553-559.
22. Nordström AL, Farde L, Nyberg S, et al. D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry. 1995;152: 1444-1449.
23. Jensen NH, Rodriguiz RM, Caron MG, et al. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine s antidepressant activity. Neuropsychopharmacology. 2008;33: 2303-2312.
24. Goldstein JM, Christoph G, Grimmk S, et al. Unique mechanism of action for the antidepressant properties of the atypical antipsychotic quetiapine (poster). Presented at the Society of Biological Psychiatry s 62nd Annual Convention & Scientific Program; May 17-19, 2007; San Diego, CA.
25. Boulton DW, DeVane CL, Liston HL, et al. In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci. 2002;71: 163-169.
26. Mahar Doan KM, Humphreys JE, Webster LO, et al. Passive permeability and P-glycoprotein mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002;303: 1029-1037.
27. Wang JS, Zhu HJ, Markowitz JS, et al. Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berl). 2006;187: 415-423.
28. De Vane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: a atypical antipsychotic. Clin Pharmacokinet. 2001;40: 509-522. (Pubitemid 32738658)
29. Hiemke Ch, Dragicevic A, Gründer G, et al. Therapeutic monitoring of new antipsychotic drugs. Ther Drug Monit. 2004;26: 156-160. (Pubitemid 38501210)
30. Findling RL, Reed MD, O'Riordan MA, et al. Effectiveness, safety, and pharmacokinetics of quetiapine in aggressive children with conduct disorder. J Am Acad Child Adolesc Psychiatry. 2006;45: 792-800.
31. Mauri MC, Volonteri LS, Colasanti A, et al. Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet. 2007;46: 359-388. (Pubitemid 46686464)
32. Sparshatt A, Jones S, Taylor D. Quetiapine: dose-response relationship in schizophrenia. CNS Drugs. 20008;22: 49-68. (Pubitemid 350243366)
33. Garelis E, Sourkes TL. Sites of origin in the central nervous system of monoamine metabolites measured in human cerebrospinal fluid. J Neurosurg Psychiatry. 1973;36: 625-629.
34. Weir RL, Chase TN, Ng LKY, et al. 5-Hydroxyindoleacetic acid in the spinal fluid, relative contribution from brain and spinal cord. Brain Res. 1973;52: 409-412.
35. Potter WZ, Manji HK. Are monoamine metabolites in cerebrospinal fluid worth measuring? Arch Gen Psychiatry. 1993;50: 653-656. (Pubitemid 23229274)
36. Agnati LF, Zoli M, Stromberg I, et al. Intercellular communication in the brain: wiring versus volume transmission. Neuroscience. 1995;69: 711-726.
37. Silver R, LeSauter J, Tresco PA, et al. A diffusible coupling signal from transplanted suprachiasmatic nucleus controlling circadian locomotor rhythms. Nature. 1996;382: 810-813. (Pubitemid 26299564)
38. Scheepers FE, Gispen-de Wied CC, Westenberg HGM, et al. The effect of olanzapine treatment on monoamine metabolite concentrations in the cerebrospinal fluid of schizophrenic patients. Neuropsychopharmacology. 2004;4: 468-475.
39. Yoshimura R, Nakamura J, Ueda N, et al. Effect of risperidone on plasma free 3-methoxy-4-hydroxyphenylglycol (pMHPG) levels in schizophrenic patients: relationship among plasma concentrations of risperidone and 9- hydroxyrisperidone, pMHPG levels, and clinical improvement. Int Clin Psychopharmacol. 2000;15: 175-180. (Pubitemid 30326053)
40. Hori H, Yoshimura R, Yamada Y, et al. Effects of olanzapine levels of catecholamine metabolites, cytokines, and brain-derived neurotrophic factor in schizophrenic patients. Int Clin Psychopharmacol. 2007;22: 21-27. (Pubitemid 44950764)
41. Yoshimura R, Hori H, Sugita A, et al. Treatment with risperidone for 4 weeks increased plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) levels, but not alter plasma brain-derived neorotrophic factor (BDNF) levels in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31: 1072-1077. (Pubitemid 46810098)
42. Wittchen HU, Wunderlich U, Gruschwitz S, et al. SKID-I. Strukturiertes Klinisches Interview für DSM.IV. Achse I: Psychische Störungen. Göttingen: Hofgrefe; 1997.
43. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13: 261-276. (Pubitemid 18039085)
44. Guy W. ECDEU Assessment Manual for Psychopharmacology. Washington, DC: US Department of Health andWelfare; 1976: 534-537.
45. Fleischhacker WW, Kemmler G. The clinical relevance of percentage improvements on the PANSS score. Neuropsychopharmacology. 2007;32: 2435-2436. (Pubitemid 47587689)
46. Davis PC, Bravo O, Gehrke M, et al. Development and validation of an LC-MS/MS method for the determination of quetiapine and four related metabolites in human plasma. J Pharm Biomed Anal. 2010;51: 1113-1119.
47. Kehr J, Yoshitake T. Monitoring brain chemical signals by microdialysis. In: Grimes CA, Dickey EC, Pishko MV, eds. Encyclopedia of Sensors, Vol.6. Stevenson Ranch, CA: American Scientific Publishers; 2006: 287-312.
48. Weikop P, Yoshitake T, Kehr J. Differential effects of adjunctive methylphenidate and citalopram on extracellular levels of serotonin, noradrenaline and dopamine in the rat brain. Eur Neuropsychopharmacol. 2007;17: 658-671. (Pubitemid 47277501)
49. Little JT, Ketter TA, Mathé AA, et al. Venlafaxine but not bupropion decreases cerebrospinal fluid 5-hydroxyindoleacetic acid in unipolar depression. Biological Psychiatry. 1999;45: 285-289.
50. Mathé AA, Rudorfer MV, Stenfors C, et al. Effects of electroconvulsive treatment on somatostatin, neuropeptide Y, endothelin, and neurokinin A concentrations in cerebrospinal fluid of depressed patients: a pilot study. Depression. 1996;3: 250-256. (Pubitemid 26236129)
51. Stenfors C, Bjellerup P, Mathé AA, et al. Concurrent analysis of neuropeptides and biogenic amines in brain tissue of rats treated with electroconvulsive stimuli. Brain Res. 1995;698: 39-45.
52. Harmatz JS, Greenblatt DJ. Falling off the straight line: some hazards of correlation and regression. J Clin Psychopharmacol. 1992;12(2): 75-78.
53. Wode-Helgodt B, Fyrö B, Gullberg B, et al. Effect of chlorpromazine treatment on monoamine metabolite levels in cerebrospinal fluid in psychotic patients. Acta Psychiatr Scand. 1977;56: 129-142. (Pubitemid 8160021)
54. Härnryd C, Bjerkenstedt L, Gullberg B, et al. Time course for effects of sulpiride and chlorpromazine on monoamine metabolite and prolactin levels in cerebrospinal fluid from schizophrenic patients. Acta Psychiatr Scand. 1984;311: 75-92. (Pubitemid 14186573)
55. Kahn RS, Davidson M, Knott P, et al. Effect of neuroleptic medication on cerebrospinal fluid monoamine metabolite concentrations in schizophrenia. Arch Gen Psychiatry. 1993;50: 599-605.
56. Wieselgren IM, Lindström LH. CSF levels of HVA and 5-HIAA in drug-free schizophrenic patients and healthy controls: a prospective study focused on their predictive value for outcome in schizophrenia. Psychiatry Res. 1998;81: 101-110.
57. Banki CM. Alterations of cerebrospinal fluid 5-hydroxyindoleacetic acid, and total blood serotonin content during clozapine treatment. Psychopharmacology. 1978;56: 195-198.
58. Szymanski S, Lieberman J, Pollack S, et al. The dopamine-serotonin relationship in clozapine response. Psychopharmacology. 1993;112: 85-89. (Pubitemid 23263254)
59. Risch SC, Lewine RRJ. Clozapine therapy and increases in homovanillic acid. Arch Gen Psychiatry. 1995;52: 244.
60. Jacobsen LK, Frazier JA, Malhotra AK, et al. Cerebrospinal fluid monoamine metabolites in childhood-onset schizophrenia. Am J Psychiatry. 1997;154: 69-74. (Pubitemid 27020195)
61. Shayegan DK, Stahl SM. Atypical antipsychotics: matching receptor profile to individual patient s clinical profile. CNS Spectr. 2004;9: 6-14.
62. Emsley RA, Buckley P, Jones AM, et al. Differential effect of quetiapine on depressive symptoms in patients with partially responsive schizophrenia. J Psychopharmacol. 2003;17: 210-215. (Pubitemid 36753538)
63. Lublin H, Eberhard J, Levander S. Current therapy issues and unmet clinical needs in the treatment of schizophrenia: a review of the new generation antipsychotics. Int Clin Psychopharmacol. 2005;20: 183-198. (Pubitemid 40896373)
64. De Lange E. Danhof M. Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting. Implications of the barriers between blood and brain. Clin Pharmacokinet. 2002;41: 691-703. (Pubitemid 34948192)
65. Harvey PD, Hassman H, Mao L, et al. Cognitive functioning and acute sedative effects of risperidone and quetiapine in patients with stable bipolar I disorder: a randomized, double-blind, crossover study. J Clin Psychiatry. 2007;68: 1186-1194. (Pubitemid 47395620)
66. Nutt DJ. The role of dopamine and norepinephrine in depression and antidepressant treatment. J Clin Psychiatry. 2006;67: 3-8. (Pubitemid 44078106)